Safe and Effective Medicines for Children Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Safe and Effective Medicines for Children. - Washington DC | National Academy of Sciences | 2012. - 351 Pages

The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.

ISBN: 978-0-309-22549-6 = Safe and Effective Medicines for Children Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. accessed April accessed March 23 adalimumab adolescents adverse events Approval letter assess becaplermin BLA Number BPCA and PREA CDER Chapter Clinical review clinical trials ClinicalTrials.gov committee conducted under BPCA Crohn’s disease dosing Drug Administration etanercept ethical Evaluation and Research example extrapolation FDA FDA’s Food and Drug Health hemophilia human immune globulin incentives indication infants infection infliximab IOM issued juvenile idiopathic arthritis Labeled pediatric use(s labeling changes MD medications monoclonal antibodies Name Trade Name NDA neonates NIH off-label omalizumab Original Approval Date Orphan Drug pediatric age groups pediatric drug studies pediatric exclusivity Pediatric Information pediatric patients pediatric population Pediatric Research Pediatric Rule pediatric studies percent pharmacokinetic pharmacokinetic studies pharmacology placebo postmarket PREA requirements psoriasis recombinant requested studies requested under BPCA required under PREA Safety and effectiveness safety and efficacy Silver Spring specific sponsors studies with neonates Study information therapy tion treatment type 1 diabetes written requests Xolair.